Media stories about Eli Lilly and (NYSE:LLY) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eli Lilly and earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.2907107264517 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Autoimmune Disease Therapeutics Market Analysis, a Size nd Forecast Report 2016-2026 (mynewsdesk.com)
- Eli Lilly: Can Sales Grow Without M&A? (finance.yahoo.com)
- FY2019 EPS Estimates for Eli Lilly and Company (LLY) Decreased by Analyst (americanbankingnews.com)
- Novo’s semaglutide beats Lilly’s dulaglutide in late-stage study in type 2 diabetics; shares ahead 3% (seekingalpha.com)
- Drug companies are growing less generous in helping patients pay for meds – Los Angeles Times (latimes.com)
Eli Lilly and (NYSE LLY) traded down 0.94% on Friday, hitting $77.07. The company’s stock had a trading volume of 4,061,282 shares. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.72. The firm has a market cap of $81.31 billion, a price-to-earnings ratio of 33.35 and a beta of 0.34. The firm has a 50 day moving average of $82.39 and a 200 day moving average of $81.90.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the firm posted $0.86 EPS. Eli Lilly and’s revenue for the quarter was up 7.8% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.
LLY has been the topic of a number of recent analyst reports. BMO Capital Markets set a $71.00 price target on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, April 25th. Argus downgraded Eli Lilly and from a “buy” rating to a “hold” rating and raised their target price for the stock from $64.18 to $81.00 in a research report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reissued a “buy” rating and issued a $92.00 target price (down from $94.00) on shares of Eli Lilly and in a research report on Saturday, April 29th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 target price on shares of Eli Lilly and in a research report on Tuesday, May 16th. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and in a research report on Sunday, May 21st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $88.27.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by BNB Daily and is owned by of BNB Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/eli-lilly-and-lly-given-media-impact-score-of-0-24-updated-updated-updated.html.
In other news, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares in the company, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 over the last three months. 0.20% of the stock is currently owned by insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.